VMD: Top line YoY growth (core business), 4X the adj. EBITDAYoY growth for the core business continued for another quarter in a row with VMD reporting 11% YoY revenue growth.
VMD also maintained a fortress balance sheet with a strong net cash position of $24 million.
With adj. EBITDA at almost $30 million for 2021, VMD's Enterprise Value currently is only 4 times its adj. EBITDA.
Outlook remains bright and growth will continue in the next quarters:
"We believe organic growth trends are emerging during the periods following COVID surges," said Casey Hoyt, Viemed's CEO. "Following the Delta variant surge during the third quarter, our sales and clinical teams returned to the field in the fourth quarter eager to serve the strong demand in the market. As a result, we finished the quarter with record setting core revenues and active patient count. As we look forward to the upcoming year, we are excited to meet this demand with the innovative service offerings, which we invested in during the pandemic.”